Clinical trials
Completed Carcinoma, Hepatocellular trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
262 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 21 |
| 2009 | 11 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 12 |
| 2013 | 16 |
| 2014 | 8 |
| 2015 | 18 |
| 2016 | 9 |
| 2017 | 14 |
| 2018 | 18 |
| 2019 | 22 |
| 2020 | 17 |
| 2021 | 27 |
| 2022 | 17 |
| 2023 | 10 |
| 2024 | 13 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 262 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 33 |
| Eastern Hepatobiliary Surgery Hospital | 30 |
| Bayer | 10 |
| Zhejiang University | 8 |
| Bristol-Myers Squibb | 6 |
| Zhongda Hospital | 6 |
| First Affiliated Hospital, Sun Yat-Sen University | 5 |
| Fuda Cancer Hospital, Guangzhou | 5 |
| RenJi Hospital | 5 |
| Akeso | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 262 |
| Liver Neoplasms | 31 |
| Liver Diseases | 7 |
| Carcinoma | 5 |
| Hepatitis B | 5 |
| Neoplasms | 5 |
| Digestive System Neoplasms | 4 |
| Fibrosis | 4 |
| Neoplasm Metastasis | 3 |
| Recurrence | 3 |
Trials
Showing 1 to 25 of 262. Each trial links to its page on Pharma Observatory.
162 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.